天津医药

天津医药 ›› 2020, Vol. 48 ›› Issue (12): 1240-1243.doi: 10.11958/20200785

• 综述 • 上一篇    下一篇

沙库巴曲缬沙坦抑制心脏重构的研究进展

段骁睿，李广平   

  1. 天津市心血管病离子与分子机能重点实验室，天津医科大学第二医院心脏科，天津心脏病学研究所（邮编300211）
  • 收稿日期:2020-04-01 修回日期:2020-09-08 出版日期:2020-12-15 发布日期:2020-12-13
  • 通讯作者: 李广平 E-mail:tjcardiol@126.com
  • 作者简介:段骁睿（1994），男，硕士在读，主要从事心房纤维化的机制研究
  • 基金资助:
    国家自然科学基金资助项目（81570304）

Research progress on the inhibition of cardiac remodeling by Sacubitril/Valsartan

DUAN Xiao-rui, LI Guang-ping   

  1. Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
  • Received:2020-04-01 Revised:2020-09-08 Published:2020-12-15 Online:2020-12-13
  • Contact: LI Guang-ping E-mail:tjcardiol@126.com

PDF (PC)

6604

摘要： 心脏重构是心血管疾病发生、发展的重要病理生理基础，与患者预后关系密切。沙库巴曲缬沙坦（LCZ696）是一种血管紧张素受体脑啡肽酶抑制剂，可同时作用于肾素-血管紧张素-醛固酮系统（RAAS）和利钠肽系统，主要用于治疗射血分数降低的心力衰竭。在不同类型的心血管疾病中，与肾素-血管紧张素系统抑制剂（RASI）比较，LCZ696能够显著抑制心脏重构，改善心功能及心血管病预后。本文就LCZ696对心脏重构抑制作用的机制及研究现状作一综述。

关键词: 心力衰竭, 心肌梗死, 心肌疾病, 心脏重构, 沙库巴曲缬沙坦

Abstract: Cardiac remodeling is an important pathophysiological basis for the occurrence and development of cardiovascular disease and is closely related to the prognosis of patients. LCZ696 is an angiotensin receptor neprilysin inhibitor, which acts on both renin-angiotensin-aldosterone system (RAAS) and natriuretic peptide system. It is mainly used in the treatment of heart failure with decreased ejection fraction. Recent studies have shown that compared with renin-angiotensin system inhibitor (RASI), LCZ696 can significantly inhibit cardiac remodeling and improve cardiac function and prognosis in different types of cardiovascular diseases. This article reviews the mechanism and research status of the inhibitory effect of LCZ696 on cardiac remodeling.

Key words: heart failure, myocardial infraction, cardiomyopathies, cardiac remodeling, sacubitril and valsartan

中图分类号: